Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma

scientific article published on 8 March 2016

Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S11605-016-3108-0
P698PubMed publication ID26956004
P5875ResearchGate publication ID297678340

P50authorNabeel BardeesyQ30004507
Carlos Fernández-del CastilloQ40930249
Kevin M HaigisQ87900780
Keith D LillemoeQ103302432
P2093author name stringDavid T Ting
Andrew L Warshaw
Andrew X Zhu
Lipika Goyal
Vikram Deshpande
Nabeel Bardeesy
Cristina R Ferrone
Aram F Hezel
Ioannis T Konstantinidis
P2860cites workProfiling critical cancer gene mutations in clinical tumor samplesQ21562343
Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumorsQ24535796
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genesQ28307762
Pancreatic cancerQ29616288
Outcome of treatment for distal bile duct cancerQ34416917
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institutionQ34578979
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancerQ34618537
Distinguishing Pancreatic Carcinoma From Other Periampullary Carcinomas by Analysis of Mutations in the Kirsten-ras OncogeneQ36784748
Pancreatic adenocarcinoma: the actual 5-year survivorsQ37008577
Extrahepatic cholangiocarcinoma: a comparison of patients with resected proximal and distal lesions.Q37316584
Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre raQ37457763
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.Q37474061
Ki-ras point mutations and proliferation activity in biliary tract carcinomasQ39999643
Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-upQ45071353
Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?Q45661541
High frequency of K-ras mutations in biliary duct carcinomas of cases with a long common channel in the papilla of Vater.Q53413496
High-throughput oncogene mutation profiling in human cancerQ57693480
Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysisQ73031231
Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ductsQ73704618
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experienceQ79369906
P433issue5
P921main subjectbile duct carcinomaQ11611688
P304page(s)953-959
P577publication date2016-03-08
P1433published inJournal of Gastrointestinal SurgeryQ15764393
P1476titleIntra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma
P478volume20

Reverse relations

cites work (P2860)
Q49825838Bile duct angulation and tumor vascularity are useful radiographic features for differentiating pancreatic head cancer and intrapancreatic bile duct cancer
Q39167413Cholangiocarcinoma: classification, diagnosis, staging, imaging features, and management
Q38911733Intrapancreatic distal common bile duct carcinoma: Analysis, staging considerations, and comparison with pancreatic ductal and ampullary adenocarcinomas.

Search more.